Agents Used in Antiretroviral Therapy

  • Authors: Philip Grant, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 7/19/21 (What's New)

Summary

  • In 2021, injectable cabotegravir plus injectable rilpivirine was approved for the treatment of HIV infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine[FDA CAB RPV]
  • The ATLAS study showed noninferiority of switching to monthly intramuscular injections of [drug: cabotegravir] plus rilpivirine (following a short lead-in with oral formulations of both drugs) vs continued baseline ART in patients on stable ART[Swindells 2020]
  • The FLAIR study showed noninferiority of monthly intramuscular injections of [drug: cabotegravir] plus rilpivirine (following a short lead-in with oral formulations of both drugs) vs abacavir/dolutegravir/lamivudine in patients with stable virologic suppression following 20 weeks of initial ART with abacavir/dolutegravir/lamivudine[Orkin 2020]

Action required